{"url_path":"/sec/qncx/8-k/2026-06-26/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-285572-index.html","accession_number":"0001193125-26-285572","cik":"0001662774","ticker":"QNCX","issuer_name":"Quince Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-285572-index.html","primary_entity_key":"0001662774","primary_entity_name":"Quince Therapeutics, Inc."},"word_count":411,"has_tables":true,"body_markdown":"8-K/A\n\ntrue 0001662774 0001662774 2026-06-26 2026-06-26\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n \n\n \n\nFORM 8-K/A\n\n(Amendment No. 1)\n\n \n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 OR 15(d)\n\nof The Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): June 26, 2026\n\n \n\n \n\nQUINCE THERAPEUTICS, INC.\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n\n \n\nDelaware\n \n001-38890\n \n90-1024039\n\n(State or other jurisdiction\n\nof incorporation)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(IRS Employer\n\nIdentification No.)\n\n \n\n611 Gateway Boulevard, Suite 273\n \n\nSouth San Francisco, California\n \n94080\n\n(Address of principal executive offices)\n \n(Zip Code)\n\nRegistrant’s telephone number, including area code: (415) 910-5717\n\nNot Applicable\n\n(Former name or former address, if changed since last report)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\n\nSymbol(s)\n\n \n\nName of each exchange\n\non which registered\n\nCommon Stock, par value $0.001 per share\n \nQNCX\n \nNasdaq Global Select Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\nExplanatory Note\n\nThis Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2026 (the “Original Form 8-K”) by Quince Therapeutics, Inc. The sole purpose of this Amendment is to correct the description of the reverse stock split described in Item 3.03 of the Original Form 8-K. This Current Report on Form 8-K/A hereby amends and restates in its entirety Item 3.03 of the Original Form 8-K to correct the error. The Original Form 8-K otherwise remains unchanged."}